Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Know Your Force: Study Shows Value Of Contact-Force-Sensing Ablation Catheter

This article was originally published in The Gray Sheet

Executive Summary

Results of the first major trial evaluating Biosense Webster’s contact-force-sensing ThermoCool SmartTouch catheter show that stability of contact between the ablation catheter and the ablated tissue substantially improves the effectiveness of cardiac ablation for atrial fibrillation, but the average contact force applied during the procedure does not appear to make a difference.

You may also be interested in...



News Briefs: FDA Approves AF Catheter; Tax Reform Proposal; Renal Denervation

FDA approved a PMA supplement for Biosense Webster’s Thermocool SmartTouch, the first FDA-approved ablation catheter that can measure contact force in real time. J&J earns a CE mark for its Renlane renal denervation system. More news briefs.

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel